Gene Bio Tech진바이오텍
086060 · KOSDAQ · ₩086060 · 진바이오텍
₩5,140▲ ₩60 (1.18%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 17.3% | 15.8% | 16.3% | 17.4% | 12.7% | 12.1% |
| Operating margin | 5.1% | 4.3% | 4.6% | 5.0% | 2.0% | −0.3% |
| Net margin | 4.1% | 4.2% | 3.5% | 3.3% | 1.8% | −0.8% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −1.6% | +9.4% | +4.4% | −4.0% | +31.8% | — |
| Operating income growth | +15.7% | +2.0% | −2.8% | +136.6% | +902.5% | — |
| Net income growth | −3.1% | +32.2% | +10.6% | +70.1% | +408.8% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 6.6% | 7.2% | 5.8% | 5.5% | 3.4% | −1.1% |
| Return on assets | 4.7% | 5.1% | 4.2% | 4.0% | 2.4% | −0.8% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 42.7% | 37.5% | 41.2% | 36.7% | 40.1% | 37.4% |
| Net debt to equity | −18.2% | −18.3% | −15.2% | −20.3% | 12.1% | 6.2% |
| Current ratio | 313.3% | 348.2% | 304.0% | 339.6% | 290.6% | 298.3% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Gene Bio Tech / 진바이오텍 / 086060 / KRX:086060
Source: KRX statistical information